Gastrointestinal Cancer

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Dostarlimab monotherapy met the primary end point of sustained clinical complete response at 12 months in the phase 2 AZUR-1 trial.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.

Tanios S. Bekaii-Saab, MD, discusses FIGHT-302 data showing frontline pemigatinib significantly improves PFS in FGFR2-positive cholangiocarcinoma.

In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.

The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.

First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.

Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.

Tanios S. Bekaii-Saab, MD, discusses the clinical significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive CCA.

Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.

The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.

Christopher Lieu, MD, discusses the evolving clinical role of ctDNA in GI oncology, including MRD-guided treatment decisions and liquid biopsy vs tissue testing in mCRC.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Need a refresh on the current regulatory landscape for GI oncology? We have it covered. Here's everything that moved the needle across GI malignancies this month.

Two Onc Docs provides a review of data from RASolute 302 of daraxonrasib for the second-line treatment of metastatic pancreatic adenocarcinoma.

Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.